An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland

Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’

“…This opposite result in cost for FCM versus IIM compared to the base case analysis, now in favor of IIM, was not mentioned in either the discussion or in the conclusion. The cost advantage of IIM over FCM by saving of infusions has also been reported in other cost comparison analyses in IBD patients [12][13][14].…”

Intravenous iron sucrose vs. blood transfusion in the management of moderate postpartum iron deficiency anemia: A non-randomized quasi-experimental study

“…However, some recent trials suggest that a single dose (1g) of infused IV iron carboxymaltose is superior to multiple doses of IV iron sucrose, which should also be considered. Besides, ferumoxytol and iron derisomaltose, both of which are single infusion formulations might an alternative to iron sucrose and iron carboxymaltose (Adkinson et al, 2018;Pollock and Muduma, 2021;Rognoni et al, 2016). Another major limitation of the present study was the clinical outcomes in the mother or secondarily in the offspring was not considered.…”

Management of iron‐deficiency anemia following acute gastrointestinal hemorrhage: A narrative analysis and review

“…While there have been evaluations of the cost-effectiveness of different iron therapies in patients with IDA, [26][27][28][29] we are unaware of any such analyses specifically in the context of acute GIB-related ID/IDA. Delays in the administration of iron replacement are common and likely impact both direct medical costs and indirect costs in terms of the negative effect on the patient's QoL and productivity losses.…”